Adjuvant Nivolumab Displays Survival Benefits in High-Risk Resected Melanoma

Source: OncLive, December 2020

Adjuvant nivolumab (Opdivo) demonstrated clinically meaningful improvements in relapse-free survival (RFS), overall survival (OS), and distant metastasis-free survival (DMFS) vs placebo in patients with high-risk resected melanoma, even after accounting for disease stage and post-recurrence survival, supporting the use of the anti–PD-1 antibody as a standard adjuvant therapy, according to findings from an indirect treatment comparison of the phase 3 CheckMate-238 and EORTC 18071 trials that were presented during the 2020 SITC Annual Meeting.

Because the trials differed in staging, a subset indirect treatment comparison analysis accounted only for patients with stage IIIB and IIIC disease, which were common populations in both trials.